CytomX reports Q2 2026 results, advances Varseta-M toward first registrational study
CytomX said enrollment in its lead ADC's Phase 1 trial is finished and it plans to start a registrational study in the first half of 2027, alongside an expanded Regeneron deal.
CytomX Therapeutics reported second quarter 2026 results on August 6, 2026, with several updates on its lead program, varsetatug masetecan (Varseta-M), an EpCAM-targeted antibody drug conjugate. The company said all 113 patients planned for the Phase 1 monotherapy trial in colorectal cancer have been enrolled across dose escalation, expansion, and optimization phases, with the dose optimization cohorts reaching their target of 40 patients by the end of April 2026 at 8.6 mg/kg and 10 mg/kg doses given every three weeks.1 CytomX said it expects a Phase 1 data update by the end of 2026 aimed at selecting a dose for later-stage development.1 The company plans to meet with the FDA to align on a registrational study design, with initiation targeted for the first half of 2027.1
Other Varseta-M work is also moving forward. A Phase 1 combination trial with bevacizumab in late-line metastatic colorectal cancer is ongoing, with initial data expected in the first half of 2027, and a separate Phase 1/2 combination study adding 5-fluorouracil and leucovorin for second-line disease is set to begin in the fourth quarter of 2026.1 The company also plans to open Phase 1 expansion cohorts in the third quarter of 2026 for gastric/GEJ, pancreatic, and biliary tract cancers.1
For CX-801, monotherapy dose escalation has reached its fourth dose level, the combination arm with Keytruda has cleared its third dose level, and initial combination data are expected in the first half of 2027.1
On the corporate side, CytomX expanded its Regeneron collaboration in June 2026, received a $37.0 million payment in July for two newly selected targets, and said Regeneron holds an option on up to six more targets, bringing potential deal value to about $4.0 billion.1
CytomX ended the quarter with $330.3 million in cash, cash equivalents, and investments, which it said gives it a runway to at least the second half of 2028, not counting the $37.0 million Regeneron payment received in July.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.